Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peri-Operative Glucocorticoid Use in Odontogenic Infections
NCT05951504Phase 3
Key facts
- Status
- Completed
- Start
- Jun 2022
- Primary completion
- Mar 2023
- Countries
- 1
- Sponsor
- University of Manitoba
- Modality
- Orthosteric Ligands
- Conditions
- odontogenic infection (OI)
01
Overview
Phase 3, randomised, open-label trial of methylprednisolone injection in odontogenic infection (OI) (2 arms), sponsored by University of Manitoba. Primary endpoints: Length of Hospital Admission, White Blood Cell Count and 3 more. Started Jun 2022; status: completed.
02
Design
2 arms- Study design
- RandomizedOpen-label
Solumedrol 1 Dose
1 dose of Solumedrol 125mg IV at surgery
Solumedrol 4 Dose
1 dose of Solumedrol 125mg IV at surgery + 3 doses q6h
03
Who it enrols
Adult patients with cervicofacial infection of odontogenic origin requiring hospital admission and surgery. Excludes patients with contraindications to steroids (e.g., uncontrolled diabetes, renal disease, psychosis, pregnancy) or non-odontogenic infections.
04
Endpoints
Primary
Length of Hospital Admission
White Blood Cell Count
C-Reactive Protein Level
Improvement in Mouth Opening
Daily clinical examination findings
Beyond the preview
Go deeper on NCT05951504.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05951504.